You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | -239.4% | -56.0% |
| ROCE | 0.0% |
| Latest | Forecast | |
|---|---|---|
| P/E | -0.5 | 0.0 |
| PEG | 0.0 | -999,999.0 |
| Price / Revenue | 1.6 | 0.7 |
| Price / Book value | 1.4 |
| Latest | Forecast | |
|---|---|---|
| Revenue | 138.0% | -56.4% |
| PBT | 0.0% | n/a |
| EPS | 0.0% | 117.0% |
| DPS | n/a | 0.0% |
| Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2019-12-31 | 0.72 | -9.07 | -7.55p | -22.4 | 0.0 | n/a | n/a | 0.0% |
| 2020-12-31 | 10.39 | -1.89 | -1.89p | -31.8 | 0.0 | n/a | n/a | 0.0% |
| 2021-12-31 | 1.52 | -19.91 | -10.00p | -4.3 | 0.0 | n/a | n/a | 0.0% |
| 2022-12-31 | 5.50 | -49.43 | -21.00p | -0.3 | 0.0 | n/a | n/a | 0.0% |
| 2023-12-31 | 13.09 | -32.38 | -5.00p | -1.3 | 0.0 | n/a | n/a | 0.0% |
| Shield Therapeutics reports strong quarter for Accrufer Sharecast News | 29 Oct |
|---|---|
| Shield Therapeutics announces promising paediatric trial results Sharecast News | 25 Sep |
| Shield Therapeutics iron deficiency treatment approved in Canada Sharecast News | 27 Aug |
| Business Update | 21-Nov-24 07:01 |
|---|---|
| Q3 Trading Update | 29-Oct-24 07:01 |
| Results from Phase 3 paediatric study | 25-Sep-24 07:01 |
| Interim results | 04-Sep-24 07:01 |
| ACCRUFeR® Approved by Health Canada | 27-Aug-24 07:01 |